Skip to main content

CAR-T Therapies

Featured Article
In a recent case study, CAR-T therapy targeting the CD30 molecule promoted a durable remission in a patient with multiply relapsed enteropathy-associated T-cell lymphoma after previous allogeneic…
Recent research shows that criteria for inclusion and exclusion in clinical trials of CAR‐T therapy for hematologic malignancies are highly variable and bring to light the need for a more…

Insights

Currently, chimeric antigen receptor T-cell (CAR-T) therapies are regulated as drugs—often leading to higher prices and barriers to access for patients, as well as financial strains for hospitals. However, in a recent insights article in JAMA Health…
Gary Goldstein, business manager of the Blood and Marrow Transplant Program at Stanford Health Care, discusses the changes needed for increased CAR-T administration in the outpatient setting as well as commercial and provider concerns about the…
An interview with Nicole M Trask, PharmD, a clinical consultant pharmacist at UMass Medical School and secretary of the AMCP’s Northeast Regional Affiliate.
An interview with Russel J Spjut, PharmD, formulary management clinical pharmacist and consultant at Formulary Intel Consulting.

Interactive Features

True or False: Criteria for inclusion and exclusion in clinical trials of chimeric antigen receptor T-cell therapy for hematologic malignancies are highly variable and bring to light the need for a more standardized approach to patient enrollment.
By Julie Gould Podcast Series:  In this episode, Steven Albelda, MD, professor of medicine at the University of Pennsylvania, Pulmonary Division, discusses a $10 million grant that Penn Medicine recently received from the National…
By Julie Gould Podcast Series: In this episode, Elizabeth Budde, MD, PhD, assistant professor in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope, discusses recommendations that were recently created by a…
By Zachary Bessette Podcast Series: Gary Goldstein, business manager of the Blood and Marrow Transplant Program at Stanford Health Care, discusses the changes needed for increased CAR-T administration in the outpatient setting as well as…
Back to Top